Phillip J. Koo, MD

Oncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.

Alicia Morgans, MD, MPH, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.

Experts share their thoughts on sequencing hormonal agents and patient selection for clinical trials.

A review of recent data from the TheraP trial.

Tanya Dorff, MD, explains safety and efficacy data from the CARD trial.

Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.

A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.

A discussion on the use of lutetium-PSMA-617 for prostate cancer treatment.

Experts in genitourinary oncology present data from the VISION clinical trial, studying patients with PSMA-positive metastatic castration-resistant prostate cancer.

Dr Ulka Vaishampayan presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.

Phillip J. Koo, MD, provides a detailed explanation of the process of PSMA-PET imaging scans for prostate cancer.

Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.

In an interview with Targeted Oncology™, Phillip J. Koo, MD, discusses both the role of novel PSMA tracers in prostate cancer imaging and the promise that theranostics, including LuPSMA, hold for prostate cancer therapy.

In this second video of the series, Phillip J. Koo, MD, of the Banner MD Anderson Cancer Center explains the role of nuclear imaging (PET) and PSMA in the diagnosis and treatment of prostate cancer.